• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Dr. Tashjian joins Potentia scientific advisory board

Article

Louisville, KY-Potentia Pharmaceuticals has appointed Armen H. Tashjian Jr., MD, to its scientific advisory board.

Louisville, KY-Potentia Pharmaceuticals has appointed Armen H. Tashjian Jr., MD, to its scientific advisory board.

Dr. Tashjian is an emeritus professor of biological chemistry and molecular pharmacology, Harvard Medical School, Boston, where his research focuses on the biochemical and molecular mechanisms of signal transduction with an emphasis on neuropeptides and their receptors.

A second long-term interest has been on intracellular and extracellular calcium metabolism and skeletal biology and pharmacology. Dr. Tashjian founded the Department of Molecular and Cellular Toxicology at the Harvard School of Public Health, where he is an emeritus professor of toxicology. Under his guidance, this department was at the forefront of discovering mechanisms of toxicity of environmental chemicals and therapeutic agents.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.